Ovid Therapeutics (OVID) Competitors $1.28 +0.02 (+1.59%) Closing price 04:00 PM EasternExtended Trading$1.27 -0.01 (-0.78%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OVID vs. FDMT, ALT, ALDX, FHTX, LRMR, CTNM, DMAC, AMRN, TECX, and KRROShould you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include 4D Molecular Therapeutics (FDMT), Altimmune (ALT), Aldeyra Therapeutics (ALDX), Foghorn Therapeutics (FHTX), Larimar Therapeutics (LRMR), Contineum Therapeutics (CTNM), DiaMedica Therapeutics (DMAC), Amarin (AMRN), Tectonic Therapeutic (TECX), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. Ovid Therapeutics vs. Its Competitors 4D Molecular Therapeutics Altimmune Aldeyra Therapeutics Foghorn Therapeutics Larimar Therapeutics Contineum Therapeutics DiaMedica Therapeutics Amarin Tectonic Therapeutic Korro Bio Ovid Therapeutics (NASDAQ:OVID) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Is OVID or FDMT more profitable? Ovid Therapeutics has a net margin of -574.44% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. 4D Molecular Therapeutics' return on equity of -40.15% beat Ovid Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ovid Therapeutics-574.44% -58.87% -43.18% 4D Molecular Therapeutics -594,375.81%-40.15%-36.43% Does the media favor OVID or FDMT? In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Ovid Therapeutics. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 2 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 1.15 beat 4D Molecular Therapeutics' score of 1.13 indicating that Ovid Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, OVID or FDMT? Ovid Therapeutics has higher revenue and earnings than 4D Molecular Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvid Therapeutics$570K159.69-$26.43M-$0.53-2.424D Molecular Therapeutics$40K7,939.00-$160.87M-$3.53-1.93 Do insiders and institutionals have more ownership in OVID or FDMT? 72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 13.1% of Ovid Therapeutics shares are held by company insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, OVID or FDMT? Ovid Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.85, meaning that its share price is 185% more volatile than the S&P 500. Do analysts recommend OVID or FDMT? Ovid Therapeutics currently has a consensus target price of $3.10, indicating a potential upside of 142.19%. 4D Molecular Therapeutics has a consensus target price of $30.40, indicating a potential upside of 347.06%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Ovid Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ovid Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.174D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64 Summary4D Molecular Therapeutics beats Ovid Therapeutics on 9 of the 17 factors compared between the two stocks. Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVID vs. The Competition Export to ExcelMetricOvid TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.60M$3.15B$5.78B$10.19BDividend YieldN/A2.33%5.73%4.61%P/E Ratio-2.4221.2474.8626.40Price / Sales159.69467.56543.78125.99Price / CashN/A44.4425.8129.91Price / Book1.339.6413.256.28Net Income-$26.43M-$53.20M$3.29B$270.38M7 Day Performance3.23%0.44%0.47%2.70%1 Month Performance31.96%4.26%4.60%5.99%1 Year Performance7.56%9.43%73.42%25.94% Ovid Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVIDOvid Therapeutics4.4558 of 5 stars$1.28+1.6%$3.10+142.2%+5.9%$89.60M$570K-2.4260Positive NewsFDMT4D Molecular Therapeutics2.6588 of 5 stars$6.97-4.1%$30.40+336.2%-58.1%$339.53M$40K-1.97120Positive NewsALTAltimmune2.7144 of 5 stars$3.71-1.9%$17.40+369.0%-53.8%$333.61M$20K-3.1450ALDXAldeyra Therapeutics2.3305 of 5 stars$5.70+2.5%$9.50+66.7%-10.6%$333.02MN/A-6.7110Positive NewsFHTXFoghorn Therapeutics2.7593 of 5 stars$5.75-0.3%$10.67+85.5%-46.6%$326.18M$22.60M-4.83120Positive NewsLRMRLarimar Therapeutics2.8207 of 5 stars$3.93-0.3%$18.43+368.9%-45.4%$326.14MN/A-2.5230Positive NewsCTNMContineum Therapeutics2.7337 of 5 stars$12.13+5.5%$22.75+87.6%-35.6%$322.48M$50M-5.5131Short Interest ↑DMACDiaMedica Therapeutics2.0351 of 5 stars$7.16+16.6%$12.33+72.3%+57.6%$317.37MN/A-10.3820High Trading VolumeAMRNAmarin0.5439 of 5 stars$14.77-3.7%$12.00-18.8%+25.1%$317.07M$228.61M-4.02360TECXTectonic Therapeutic2.5225 of 5 stars$16.31-2.9%$80.29+392.2%-1.5%$314.36MN/A-4.04120Gap DownKRROKorro Bio2.1469 of 5 stars$32.92-0.8%$86.83+163.8%-25.8%$311.59M$2.27M-3.3870Positive News Related Companies and Tools Related Companies FDMT Alternatives ALT Alternatives ALDX Alternatives FHTX Alternatives LRMR Alternatives CTNM Alternatives DMAC Alternatives AMRN Alternatives TECX Alternatives KRRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVID) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OVID Stock Alerts